Home > Journals > The Journal of Cardiovascular Surgery > Past Issues > The Journal of Cardiovascular Surgery 2017 August;58(4) > The Journal of Cardiovascular Surgery 2017 August;58(4):528-34

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

ORIGINAL ARTICLE  VASCULAR SECTION 

The Journal of Cardiovascular Surgery 2017 August;58(4):528-34

DOI: 10.23736/S0021-9509.16.09685-3

Copyright © 2016 EDIZIONI MINERVA MEDICA

language: English

Paclitaxel-coated versus plain old balloon angioplasty for the treatment of infrainguinal arterial disease in diabetic patients: the Belgian diabetic IN.PACT Trial

Erik DEBING 1 , Dimitri AERDEN 1, Alain VANHULLE 1, 2, Sarah GALLALA 1, Karl, von KEMP 1, on behalf of TRIAL Investigators 

1 Department of Vascular Surgery, Brussel University Hospital, Brussels, Belgium; 2 Department of Surgery, St Jan Brugge University Hospital, Oostende Campus, Ostend, Belgium


PDF


BACKGROUND: Several trials have shown that drug coated balloon (DCB) angioplasty reduce the rates of restenosis in the femoropopliteal artery. This controlled, prospective, multicenter study was designed to demonstrate the efficacy of DCB to inhibit restenosis of the infrainguinal arteries in an exclusive diabetic population.
METHODS: Between 2012 and 2014, 106 diabetic patients with symptomatic peripheral arterial disease (PAD) were enrolled at 11 sites in Belgium, 54 treated with DCB angioplasty and 52 treated with plain old balloon angioplasty (POBA). The primary endpoint of the study are the primary patency, mean diameter restenosis and binary restenosis of the treated sites at 6 months without re-intervention in the interim.
RESULTS: The 6-month mean diameter restenosis was significantly lower in the DCB arm than in the POBA group (29±36% vs. 46±35%, P=0.032) and the binary (≥50% diameter stenosis) restenosis rate was signicantly lower in DCB patients compared with the POBA’s (27% vs. 49%, P=0.03). The primary patency was significantly better in the paclitaxel coated balloon group (73% vs. 51%, P=0.03). The 6-month adverse effects rates were 5.5% in the POBA and 5.7% in the DCB arm.
CONCLUSIONS: The treatment of diabetic PAD of the infra-inguinal arteries with the DCB provides a bettter primary patency rate compared with the plain old balloon angioplasty. The use of DCB did not increase the number of major adverse clinical events when compared with those seen with the use of the uncoated balloons.


KEY WORDS: Randomized controlled trial - Diabetes mellitus - Paclitaxel - Angioplasty

top of page